市場調査レポート

商品コード

1762536

うつ病性障害市場：業界動向と世界の予測 - うつ病タイプ別、分子タイプ別、治療タイプ別、投与経路別、主要地域別

Depressive Disorders Market: Industry Trends and Global Forecasts - Distribution by Type of Depression, Type of Molecule, Type of Therapy, Route of Administration and Key Geographical Regions

出版日: 2025年07月04日
発行: Roots Analysis
ページ情報: 英文 242 Pages
納期: 即日から翌営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,799 705,884円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,029,482円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,559,006円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,647,472円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.09円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

うつ病性障害市場：概要

世界のうつ病性障害の市場規模は、予測期間中に有利なCAGRで成長すると予測されています。

市場セグメンテーションと機会分析は、以下のパラメータでセグメント化されています：

うつ病タイプ

大うつ病性障害
双極性障害
産後うつ病
治療抵抗性うつ病
その他

分子タイプ

低分子
生物学的製剤

治療タイプ

単剤療法
併用療法
併用療法
逐次療法

投与経路

経口
非経口
経鼻
経皮

主要地域

北米
欧州
アジア太平洋

うつ病性障害市場：成長と動向

うつ病は、絶え間ない悲しみと外部刺激への無関心を特徴とする精神疾患です。特筆すべきことに、この慢性疾患は世界中で精神障害の主な原因のひとつと考えられています。実際、全世界で3億人を超えるあらゆる年齢層の人々がうつ病に苦しんでいることは特筆に値します。さらに、うつ病性障害は米国で年間約2,100億米ドルの経済的負担を引き起こしていると推定されています。うつ病は広く蔓延し、大きな影響を及ぼしているにもかかわらず、高所得国ではうつ病患者の50％以下しか治療を受けておらず、低所得国では10％以下にまで落ち込んでいます。その結果、多数のブランド薬と150以上のジェネリック医薬品が、うつ病患者の治療薬としてFDAに承認されています。ジェネリック医薬品や他のブランド薬が利用可能であるにもかかわらず、患者からはより優れた抗うつ薬の必要性が声高に叫ばれています。

その結果、より優れた抗うつ薬に対する需要の高まりから、利害関係者はうつ病を治療するための新しい作用機序を持つ介入薬や薬剤／治療法の候補を開発するためにさまざまな取り組みを行っています。最近では、利害関係者は個別化アプローチにより依存し始め、経頭蓋直流刺激療法（tDCS）やケタミンなどの新しい療法を取り入れ、腸内マイクロバイオームとうつ病の関連を探求しています。

うつ病性障害市場：主要インサイト

当レポートでは、世界のうつ病性障害市場の現状を掘り下げ、産業内の潜在的な成長機会を特定しています。当レポートの主な調査結果は以下の通りです。

過去数年間、うつ病性障害市場は複数の臨床段階での薬剤の失敗を経験してきました。報告された様々な理由の中で、特定の臨床エンドポイントを達成できないことが最も一般的でした。

現在の市場情勢は細分化されており、小規模企業から大手製薬企業まで、65以上のうつ病治療薬候補が開発されています。
開発パイプラインにあるいくつかの分子は臨床開発の後期段階にあり、大半の薬剤は単剤療法で、経口経路でデリバリーされるように設計されています。
複数の上市済み医薬品と健全な臨床パイプラインにより、この領域における機会は、より多くの製品候補が承認されるにつれて着実に拡大すると予想されます。
大半のリード分子は単剤療法として評価されているが、開発者は特定の薬剤を補助療法や併用療法としても評価しています。
現在、うつ病治療薬のパイプラインは経口投与薬が主流であるが、経鼻や経皮といった他の投与経路も研究されています。
臨床試験は様々な地域で登録されているが、北米で実施されている試験が最も多く、臨床試験の70％以上が第II相／第III相試験で評価されています。
進化する製品状況に対応するため、医薬品開発企業は、候補品が臨床的・商業的に有能であることを保証するために多大な努力を払っています。
2010年以降、30億米ドルを超える投資が行われ、企業は投資家から積極的な支援を受けています。
Janssen Pharmaceutical、Lundbeck、Vistagen Therapeutics、武田薬品工業、大塚製薬などの企業は、うつ病性障害に関連する複数の契約を締結しています。
総額の約60％は過去3年間に投資されたものです。具体的には、3月までだけでも、この領域に携わる企業は合計で6億5,000万米ドルを調達しています。全体では、28億米ドルが、さまざまな業界の利害関係者別二次公募を通じて調達されました。
利害関係者は、製品の上市サイクルのさまざまな段階にわたって多様な商業化戦略を模索しています。特許切れが近い医薬品では、開発者はライフサイクル管理アプローチを採用すると予想されます。

うつ病性障害市場における参入企業例

AbbVie
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
GSK
H. Lundbeck
Johnson & Johnson
Merck
Pfizer
Sanofi

章の概要
成功する医薬品発売戦略：ROOTSフレームワーク
成功する医薬品発売戦略：製品の差別化
製品の開発段階に応じて採用される商業化戦略
うつ病治療薬として承認された分子
- エビリファイマイサイト（R）
- エビリファイメンテナ（R）
- レキサルティ（R）
- ヴレイラー（R）
- トリンテリックス（R）
- フェツィマ（R）
- ラツーダ（R）
- ヴィーブリッド（R）
うつ病治療に注力する企業が採用する主要な商業化戦略
結論

第12章うつ病に対するデジタル治療法

章の概要
デジタルセラピューティクスの概要
デジタル治療薬の開発と商業化への道筋
うつ病に対するデジタル治療
- スタンドアロンソフトウェアアプリケーション
- パーソナルコーチング
- AIサポート
- ゲームソリューション
結論

第13章結論

第14章付録1：表形式データ

第15章付録2：企業・団体一覧

図表

List of Tables

Table 3.1 List of FDA Approved Antidepressants
Table 4.1 Depressive Disorders: Marketed and Development Pipeline
Table 4.2 Depressive Disorders: Information on Special Designations
Table 4.3 Depressive Disorders: Information on Site of Drug Administration
Table 4.4 Depressive Disorders: Information on Drug Type, Drug Class and Mechanism of Action
Table 4.5 Depressive Disorders: Developer Overview
Table 4.6 List of Neurostimulation Devices (Invasive) for Depression
Table 4.7 List of Neurostimulation Devices (Non-Invasive) for Depression
Table 5.1 Depressive Disorders: Pipeline of Discontinued Drugs
Table 5.2 Depressive Disorders: List of Discontinued Clinical Trials
Table 5.3 Depressive Disorders: List of Discontinued Drugs (Unvalidated)
Table 6.1 Depressive Disorders: Partnerships and Collaborations
Table 7.1 Depressive Disorders: Funding and Investments
Table 7.2 Funding and Investment Analysis: Summary of Investments
Table 8.1 Clinical Trial Analysis: Emerging Molecules to Watch
Table 8.2 Clinical Trial Analysis: Most Important Trials to Watch
Table 9.1 Clinical Trial Endpoint Analysis: List of Drugs
Table 9.2 Clinical Endpoint Analysis: Key Primary Endpoints Evaluated for Major Depressive Disorder
Table 9.3 Clinical Endpoint Analysis: Key Primary Endpoints Evaluated for Bipolar Disorder / Bipolar Depression
Table 9.4 Clinical Trial Endpoint Analysis: Key Primary Endpoints Evaluated for Other Depressive Disorders
Table 11.1 Drug Snapshot: Abilify Mycite(R)
Table 11.2 Drug Snapshot: Abilify Maintena(R)
Table 11.3 Drug Snapshot: Rexulti(R)
Table 11.4 Drug Snapshot: Vraylar(R)
Table 11.5 Drug Snapshot: Trintellix(R)
Table 11.6 Drug Snapshot: Fetzima(R)
Table 11.7 Drug Snapshot: Latuda(R)
Table 11.8 Drug Snapshot: Viibryd(R)
Table 11.9 Patient Support Services on Product Websites of Drugs for Depressive Disorders: Comparative Analysis
Table 11.10 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Table 12.1 Digital Therapeutics for Depressive Disorders: List of Solutions
Table 13.1 Depressive Disorders: Summary of Competitive Insights
Table 14.1 Global Prevalence of Depression: Distribution by Gender and Age Groups
Table 14.2 Depressive Disorders: Distribution by Phase of Development
Table 14.3 Depressive Disorders: Distribution by Type of Depressive Disorder
Table 14.4 Depressive Disorders: Distribution by Type of Depressive Disorder and Phase of Development
Table 14.5 Depressive Disorders: Distribution by Type of Therapy
Table 14.6 Depressive Disorders: Distribution by Type of Molecules
Table 14.7 Depressive Disorders: Distribution by Route of Administration
Table 14.8 Depressive Disorders: Distribution by Dosing Frequency
Table 14.9 Depressive Disorders: Distribution by Type Drug and Drug Class
Table 14.10 Major Depressive Disorder: Distribution by Phase of Development
Table 14.11 Major Depressive Disorder: Distribution by Route of Administration
Table 14.12 Major Depressive Disorder: Distribution by Dosing Frequency
Table 14.13 Major Depressive Disorder: Key Players
Table 14.14 Bipolar Disorder / Bipolar Depression: Distribution by Phase of Development
Table 14.15 Bipolar Disorder / Bipolar Depression: Distribution by Route of Administration
Table 14.16 Bipolar Disorder / Bipolar Depression: Distribution by Dosing Frequency
Table 14.17 Bipolar Disorder / Bipolar Depression: Key Players
Table 14.18 Treatment-Resistant Depression: Distribution by Phase of Development
Table 14.19 Treatment-Resistant Depression: Distribution by Route of Administration
Table 14.20 Treatment-Resistant Depression: Distribution by Dosing Frequency
Table 14.21 Postpartum Depression and Depression (Type Unknown): Distribution by Phase of Development
Table 14.22 Postpartum Depression and Depression (Type Unknown): Distribution by Route of Administration
Table 14.23 Postpartum Depression and Depression (Type Unknown): Distribution by Dosing Frequency
Table 14.24 Depressive Disorders: Distribution by Year of Establishment of Developer
Table 14.25 Depressive Disorders: Distribution by Company Size (Employee Count)
Table 14.26 Depressive Disorders: Distribution of Developers by Geographical Location (Continents)
Table 14.27 Depressive Disorders: Distribution of Developers by Geographical Location (Countries)
Table 14.28 Depressive Disorders: Distribution of Developers by Type of Depressive Disorder
Table 14.29 Depressive Disorders: Key Players
Table 14.30 Failure Analysis: Cumulative Distribution of Drugs by Year of Discontinuation
Table 14.31 Failure Analysis: Distribution by Phase of Discontinuation
Table 14.32 Failure Analysis: Distribution by Mechanism of Action
Table 14.33 Failure Analysis: Distribution by Type of Depressive Disorder
Table 14.34 Failure Analysis: Key Players
Table 14.35 Failure Analysis: Distribution by Reason for Discontinuation
Table 14.36 Failure Analysis: Relative Distribution by Reasons for Discontinuation and Phase of Development
Table 14.37 Failure Analysis: Distribution of Discontinued Trials by Trial Phase and Average Time to Discontinuation
Table 14.38 Failure Analysis: Distribution of Discontinued Trials by Type of Sponsor / Collaborator
Table 14.39 Failure Analysis: Distribution of Discontinued Trials by Reason for Discontinuation
Table 14.40 Partnerships and Collaborations: Cumulative Trend of Activity, by Year
Table 14.41 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.42 Partnerships and Collaborations: Distribution by Type and Year of Partnership
Table 14.43 Partnerships and Collaborations: Distribution by Area of Focus
Table 14.44 Partnerships and Collaborations: Distribution by Type of Depressive Disorder
Table 14.45 Partnerships and Collaborations: Regional Distribution
Table 14.46 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 14.47 Partnerships and Collaborations: Most Active Players
Table 14.48 Funding and Investment Analysis: Cumulative Number of Instances by Year
Table 14.49 Funding and Investment Analysis: Cumulative Amount Invested by Year (USD Million)
Table 14.50 Funding and Investments: Average Amount Invested per Year (USD Million)
Table 14.51 Funding and Investment Analysis: High Value Deals (USD Million)
Table 14.52 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 14.53 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding (USD Million)
Table 14.54 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding
Table 14.55 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 14.56 Funding and Investment Analysis: Distribution of Funding Instances across Major Therapeutic Areas
Table 14.57 Funding and Investment Analysis: Most Active Players
Table 14.58 Clinical Trial Analysis: Cumulative Distribution of Clinical Trials by Start Year
Table 14.59 Clinical Trial Analysis: Distribution of Clinical Trials by Study Start Year and Geography
Table 14.60 Clinical Trial Analysis: Distribution of Patients Enrolled by Study Start Year
Table 14.61 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Table 14.62 Clinical Trial Analysis: Distribution by Trial Status
Table 14.63 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.64 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Recruiting Status
Table 14.65 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Trial Registration Year

List of Figures

Figure 1.1 Depressive Disorders: Scope and Competitive Insights
Figure 3.1 Depression: Key Facts
Figure 3.2 Depression: Common Signs and Symptoms
Figure 3.3 Prevalence of Depression in Major Geographical Regions
Figure 3.4 Prevalence of Depression in Major Geographical Regions by Gender
Figure 3.5 Global Prevalence of Depression: Distribution by Gender and Age Groups
Figure 3.6 Prevalence of Various Types of Depression in the US
Figure 3.7 Causes of Depression
Figure 4.1 Depressive Disorders: Distribution by Phase of Development
Figure 4.2 Depressive Disorders: Distribution by Type of Depressive Disorder
Figure 4.3 Depressive Disorders: Distribution by Type of Depressive Disorder and Phase of Development
Figure 4.4 Depressive Disorders: Distribution by Type of Therapy
Figure 4.5 Depressive Disorders: Distribution by Type of Molecule
Figure 4.6 Depressive Disorders: Distribution by Route of Administration
Figure 4.7 Depressive Disorders: Distribution by Dosing Frequency
Figure 4.8 Depressive Disorders: Distribution by Type of Drug and Drug Class
Figure 4.9 Major Depressive Disorder: Distribution by Phase of Development
Figure 4.10 Major Depressive Disorder: Distribution by Route of Administration
Figure 4.11 Major Depressive Disorder: Distribution by Dosing Frequency
Figure 4.12 Major Depressive Disorder: Key Players
Figure 4.13 Bipolar Disorder / Bipolar Depression: Distribution by Phase of Development
Figure 4.14 Bipolar Disorder / Bipolar Depression: Distribution by Route of Administration
Figure 4.15 Bipolar Disorder / Bipolar Depression: Distribution by Dosing Frequency
Figure 4.16 Bipolar Disorder / Bipolar Depression: Key Players
Figure 4.17 Treatment-Resistant Depression: Distribution by Phase of Development
Figure 4.18 Treatment-Resistant Depression: Distribution by Route of Administration
Figure 4.19 Treatment-Resistant Depression: Distribution by Dosing Frequency
Figure 4.20 Treatment-Resistant Depression: Key Players
Figure 4.21 Postpartum Depression and Depression (Type Unknown): Distribution by Phase of Development
Figure 4.22 Postpartum Depression and Depression (Type Unknown): Distribution by Route of Administration
Figure 4.23 Postpartum Depression and Depression (Type Unknown): Distribution by Dosing Frequency
Figure 4.24 Grid Analysis: Distribution of Pipeline Therapies by Phase of Development, Type of Depressive Disorder and Type of Drug
Figure 4.25 Depressive Disorders: Distribution by Year of Establishment of Developer
Figure 4.26 Depressive Disorders: Distribution by Size of Developer (Employee Count)
Figure 4.27 Depressive Disorders: Distribution of Developers by Geographical Location (Continents)
Figure 4.28 Depressive Disorders: Distribution of Developers by Geographical Location (Countries)
Figure 4.29 Depressive Disorders: Distribution of Developers by Type of Depressive Disorder
Figure 4.30 Depressive Disorders: Leading Players
Figure 4.31 Grid Analysis: Distribution by Location of Developer, Company Size (Employee Count) and Type of Depressive Disorder
Figure 5.1 Failure Analysis: Cumulative Distribution of Drugs by Year of Discontinuation
Figure 5.2 Failure Analysis: Distribution by Phase of Discontinuation
Figure 5.3 Failure Analysis: Distribution by Mechanism of Action
Figure 5.4 Failure Analysis: Distribution by Type of Depressive Disorder
Figure 5.5 Failure Analysis: Key Players
Figure 5.6 Failure Analysis: Distribution by Reason of Discontinuation
Figure 5.7 Failure Analysis: Relative Distribution by Reasons for Discontinuation and Phase of Development
Figure 5.8 Failure Analysis: Year-wise Distribution of Discontinued Trials
Figure 5.9 Failure Analysis: Distribution of Discontinued Trials by Trial Phase and Average Time to Discontinuation
Figure 5.10 Failure Analysis: Distribution of Discontinued Trials by Type of Sponsor / Collaborator
Figure 5.11 Failure Analysis: Distribution of Discontinued Trials by Geography
Figure 5.12 Failure Analysis: Distribution of Discontinued Trials by Year of Discontinuation and Geography
Figure 5.13 Failure Analysis: Distribution of Discontinued Trials by Reason of Discontinuation
Figure 5.14 Bubble Analysis: Distribution of Discontinued Trials by Year of Discontinuation, Reason of Discontinuation and Phase of Development
Figure 6.1 Partnerships and Collaborations: Cumulative Trend of Activity, by Year
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Type and Year of Partnership
Figure 6.4 Partnerships and Collaborations: Distribution by Area of Focus
Figure 6.5 Partnerships and Collaborations: Distribution by Type of Depressive Disorder
Figure 6.6 Partnerships and Collaborations: Regional Distribution
Figure 6.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 6.8 Partnerships and Collaborations: Most Active Players
Figure 6.9 Partnerships and Collaborations: Activity of Big Pharmaceutical Companies
Figure 7.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment of Developer
Figure 7.2 Funding and Investment Analysis: Cumulative Number of Instances by Year
Figure 7.3 Funding and Investment Analysis: Cumulative Amount Invested by Year (USD Million)
Figure 7.4 Funding and Investment Analysis: Average Amount Invested per Year (USD Million)
Figure 7.5 Funding and Investment Analysis: High Value Deals (USD Million)
Figure 7.6 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 7.7 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding (USD Million)
Figure 7.8 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding
Figure 7.9 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 7.10 Funding and Investment Analysis: Distribution of Funding Instances across Major Therapeutic Areas
Figure 7.11 Funding and Investment Analysis: Most Active Players
Figure 7.12 Funding and Investment Analysis: Key Investors
Figure 7.11 Funding and Investment Summary (USD Million)
Figure 8.1 Clinical Trial Analysis: Cumulative Distribution of Clinical Trials by Start Year
Figure 8.2 Clinical Trial Analysis: Distribution of Clinical Trials by Study Start Year and Geography
Figure 8.3 Clinical Trial Analysis: Distribution of Patients Enrolled by Study Start Year
Figure 8.4 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 8.5 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.6 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.7 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Recruitment Status
Figure 8.8 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Trial Registration Year
Figure 8.9 Clinical Trial Analysis: Distribution by Type of Drug Class
Figure 8.10 Clinical Trials Analysis: Most Active Industry and Non-Industry Players in Terms of Number of Trials Conducted
Figure 8.11 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.12 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Phase, Recruitment Status and Geography
Figure 8.13 Clinical Trial Analysis: Distribution of Clinical Trials by Type of Depressive Disorder and Geography
Figure 8.14 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Phase, Type of Depressive Disorder and Geography
Figure 8.15 Clinical Trial Analysis: Distribution of Clinical Trials by Type of Drug Class and Geography
Figure 8.16 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Phase, Mechanism of Action and Geography
Figure 8.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 8.18 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase, Recruitment Status and Geography
Figure 8.19 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Type of Depressive Disorder and Geography
Figure 8.20 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase, Type of Depressive Disorder and Geography
Figure 8.21 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Type of Drug Class and Geography
Figure 8.22 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase, Mechanism of Action and Geography
Figure 10.1 Clinical Commercial Attractiveness Analysis: Late-Stage Molecules Under Investigation for Treating Depressive Disorders
Figure 10.2 Clinical and Commercial Attractiveness Analysis: Late-Stage Molecules Under Investigation for Treating Major Depressive Disorder
Figure 10.3 Clinical and Commercial Attractiveness Analysis: Late-Stage Molecules Under Investigation for Treating Bipolar Disorder / Bipolar Depression
Figure 10.4 Clinical and Commercial Attractiveness Analysis: Late-Stage Molecules Under Investigation for Treating Other Depressive Disorders
Figure 11.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 11.2 Successful Drug Launch Strategy: Product Differentiation
Figure 11.3 Common Commercialization Strategies Adopted Based on Development Stage of Product
Figure 11.4 Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Focused on Depressive Disorders
Figure 11.5 Participation in Global Events: Historical Timeline
Figure 11.6 Approved Drugs for Depressive Disorders: Promotional Activities through Product Websites
Figure 11.7 Approval of Drugs in Multiple Geographies: Historical Timeline
Figure 11.8 Approval of Drugs for Multiple Indications: Historical Timeline
Figure 12.1 Prescription Digital Therapeutics: Process Map
Figure 12.2 Digital Therapeutics: Google Trends

Product Code: RA100C06

DEPRESSIVE DISORDERS MARKET: OVERVIEW

As per Roots Analysis, the global depressive disorders market is anticipated to grow at a lucrative CAGR during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Depression

Major Depression Disorder
Bipolar Disorder
Postpartum Depression
Treatment-Resistant Depression
Others

Type of Molecule

Small Molecule
Biologic

Type of Therapy

Monotherapy
Adjunctive Therapy
Combination Therapy
Sequential Therapy

Route of Administration

Oral
Parenteral
Nasal
Transdermal

Key Geographical Regions

North America
Europe
Asia-Pacific

DEPRESSIVE DISORDERS MARKET: GROWTH AND TRENDS

Depression is a mental health disorder characterized by a constant feeling of sadness and lack of interest in external stimuli. Notably, this chronic condition is considered among the leading causes of mental disability worldwide. In fact, it is worth mentioning that, globally more than 300 million people of all age groups suffer from depression. Moreover, depressive disorders are estimated to cause an economic burden of approximately USD 210 billion in the US, annually. Despite its widespread occurrence and substantial impact, less than 50% of people with this condition receive treatment in high-income countries, and this number drops to less than 10% in low-income countries. As a result, a large number of branded drugs and over 150 generic products have been approved by the FDA to treat depression among patients. Despite the availability of generics and other branded drugs, patients have voiced the need for better antidepressants.

Consequently, the rising demand for better antidepressants has led stakeholders to undertake various initiatives to develop interventions and drug / therapy candidates with novel mechanism of action to treat depression. Recently, stakeholders have begun relying more on personalized approaches, incorporating new therapies, such as Transcranial Direct Current Stimulation (tDCS) and ketamine, and exploring the link between the gut microbiome and depression.

DEPRESSIVE DISORDERS MARKET: KEY INSIGHTS

The report delves into the current state of the global depressive disorders market and identifies potential growth opportunities within industry. Some key findings from the report include:

Over the past few years, the depressive disorders market has witnessed multiple clinical stage drug failures; amongst the various reported reasons, inability to achieve specific clinical endpoints was the most common.

The current market landscape is fragmented, featuring small companies and established pharma giants, which are engaged in the development of over 65 drug candidates for treating different forms of depression.
Several molecules in the development pipeline are in the late stages of clinical development; majority of the drugs are monotherapies and designed for delivery via oral route.
With several marketed drugs and a healthy clinical pipeline, the opportunity in this domain is expected to evolve steadily as more product candidates get approved.
Majority of the lead molecules are being evaluated as monotherapies; however, developers are also evaluating certain drugs as an adjunctive or combination therapy.
Currently, the depressive drugs pipeline is dominated by orally administrable drugs; however, other routes of administration, such as nasal and transdermal, are also being investigated.
Although clinical studies are registered across various geographies, maximum number of trials are being conducted in North America; over 70% of clinical trials are evaluating drugs in Phase II / Phase III.
In lieu of the evolving product landscape, drug developers are putting in significant efforts to ensure that their candidates are clinically and commercially competent.
A substantial proportion of partnerships in this domain are focused on digital therapeutics initiatives; with over USD 3 billion investments since 2010, companies have received active support from investors.
Companies, such as Janssen Pharmaceutical, Lundbeck, Vistagen Therapeutics, Takeda Pharmaceutical and Otsuka Pharmaceutical, have signed multiple deals related to depressive disorders; majority of the aforementioned agreements were signed for R&D purpose.
Around 60% of the total amount was invested in the last three years. Specifically, till March alone, companies engaged in this domain had collectively raised USD 650 million. Overall, a sum of USD 2.8 billion was raised by various industry stakeholders through secondary offerings.
Stakeholders are exploring diverse commercialization strategies across different stages of a product's launch cycle; with drugs nearing patent expiry, developers are expected to adopt lifecycle management approaches.

Example Players in the Depressive Disorders Market

AbbVie
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
GSK
H. Lundbeck
Johnson & Johnson
Merck
Pfizer
Sanofi

DEPRESSIVE DISORDERS MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the depressive disorders market, focusing on key market segments, including [A] type of depression, [B] type of molecule, [C] type of therapy, [D] route of administration and [E] key geographical regions.
Market Landscape: A comprehensive evaluation of market landscape, based on several relevant parameters, such as [A] information on drug developer(s), [B] phase of development, [C] type of molecule, [D] type of therapy, [E] type of depression, [F] type of drug class, [G] mechanism of action, [H] dosing frequency and [I] route of administration.
Discontinued Drug Development Programs Case Study: In-depth assessment of discontinued drugs / trials, focusing on [A] the number of discontinued drug development programs, [B] year of discontinuation, [C] geographical location, [D] phase at which the development program was discontinued, [E] mechanism of action of discontinued drug, [F] disease indication, [G] reason(s) for discontinuation and [H] information on affiliated developer companies.
Partnerships and Collaborations: A detailed analysis of the deals inked by stakeholders in this domain, based on various parameters, such as [A] year of partnership, [B] type of partnership, [C] area of focus, [D] type of depressive disorder, [E] geography and [F] most active players.
Fundings and Investments: An in-depth analysis of the fundings received by players in depressive disorders domain, based on relevant parameters, such as [A] number of funding instances, [B] amount invested, [C] type of funding, [D] most active players, [E] most active investors and [F] geography.
Clinical Trial Analysis: An insightful analysis of clinical trials related to depressive disorders, based on several parameters, such as [A] trial registration year, [B] current trial status, [C] current trial phase, [D] type of depressive disorder, [E] mechanism of action, [F] leading industry and non-industry players with highest number of completed / ongoing trials, [G] regional distribution of clinical trials and [H] enrolled patient population across different geographies.
Clinical Trial Endpoints Analysis: A detailed analysis of the clinical endpoints in late-stage ongoing and planned studies, for various types of depressive disorders.
Clinical and Commercial Attractiveness Analysis: A comprehensive assessment of clinical and commercial attractiveness of pipeline molecules based on several parameters, such as [A] size of enrolled patient population, [B] route of administration, [C] therapy type and dosing frequency, [D] target patient population, [E] expected launch date and [F] size of developer company.
Key Commercialization Strategies: A detailed discussion on the various strategies that can be adopted by the drug developers across key commercialization stages including a timeline representation of the key strategies adopted.
Digital Therapeutics for Depressive Disorders Case Study: A detailed discussion on the upcoming digital health solutions for the management / treatment of depression, featuring information on the various product development pathways adopted by companies involved in this segment of the market.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
- 1.2.1. Research Assumptions
- 1.2.2. Project Methodology
- 1.2.3. Forecast Methodology
- 1.2.4. Robust Quality Control
- 1.2.5. Key Considerations
  - 1.2.5.1. Demographics
  - 1.2.5.2. Economic Factors
  - 1.2.5.3. Government Regulations
  - 1.2.5.4. Supply Chain
  - 1.2.5.5. COVID Impact / Related Factors
  - 1.2.5.6. Market Access
  - 1.2.5.7. Healthcare Policies
  - 1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. An Overview of Depression and Depressive Disorders
3.2. Signs and Symptoms of Depression
3.3. Types of Depression
3.4. Epidemiology of Depression
3.5. Causes of Depression
3.6. Diagnosis of Depression
3.7. Current Treatment Paradigms
- 3.7.1. Pharmacological Treatment
- 3.7.2. Psychological Treatment
- 3.7.3. Other Treatments
3.8. Innovative Therapeutic Strategies
3.9. Future Perspectives

4. PIPELINE REVIEW: MARKETED AND CLINICAL STAGE DRUGS

4.1. Chapter Overview
4.2. Depressive Disorders: Marketed and Development Pipeline
- 4.2.1. Analysis by Phase of Development
- 4.2.2. Analysis by Type of Depressive Disorder
- 4.2.3. Analysis by Type of Therapy
- 4.2.4. Analysis by Type of Molecules
- 4.2.5. Analysis by Route of Administration
- 4.2.6. Analysis by Dosing Frequency
- 4.2.7. Analysis by Type of Drug and Drug Class
- 4.2.8. Major Depressive Disorder
  - 4.2.8.1. Analysis by Phase of Development
  - 4.2.8.2. Analysis by Route of Administration
  - 4.2.8.3. Analysis by Dosing Frequency
  - 4.2.8.4. Key Players
- 4.2.9. Bipolar Disorder / Bipolar Depression
  - 4.2.9.1. Analysis by Phase of Development
  - 4.2.9.2. Analysis by Route of Administration
  - 4.2.9.3. Analysis by Dosing Frequency
  - 4.2.9.4. Key Players
- 4.2.10. Treatment-Resistant Depression
  - 4.2.10.1. Analysis by Phase of Development
  - 4.2.10.2. Analysis by Route of Administration
  - 4.2.10.3. Analysis by Dosing Frequency
  - 4.2.10.4. Key Players
- 4.2.11. Postpartum Depression and Depression (Type Unknown)
  - 4.2.11.1. Analysis by Phase of Development
  - 4.2.11.2. Analysis by Route of Administration
  - 4.2.11.3. Analysis by Dosing Frequency
  - 4.2.11.4. Key Players
- 4.2.12 Grid Analysis: Distribution by Phase of Development, Type of Depressive Disorder and Type of Drug
4.3. Depressive Disorders: List of Drug Developers
- 4.3.1. Analysis by Year of Establishment of Developers
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Geographical Location of Developers
- 4.3.4. Analysis by Type of Depressive Disorder
- 4.3.5. Key Developers
- 4.3.6. Grid Analysis: Distribution by Location of Developer, Company Size and Type of Depressive Disorder
4.4 Other Novel Ways to Treat Depression
- 4.4.1. Role of Neurostimulation Devices
- 4.4.2. Role of Microbiome Therapeutics

5. CASE STUDY: DISCONTINUED DRUG DEVELOPMENT PROGRAMS

5.1. Chapter Overview
5.2. Depressive Disorders: Discontinued Drugs
- 5.2.1. Analysis by Year of Discontinuation
- 5.2.2. Analysis by Phase of Discontinuation
- 5.2.3. Analysis by Mechanism of Action
- 5.2.4. Analysis by Type of Depressive Disorder
- 5.2.5. Key Players
- 5.2.6. Analysis by Reason for Discontinuation
5.3. Depressive Disorders: Discontinued Clinical Trials
- 5.3.1. Year-wise Trend of Discontinued Trials
- 5.3.2. Analysis of Discontinued Clinical Trials by Phase of Development
- 5.3.3. Analysis of Discontinued Clinical Trials by Sponsor / Collaborator
- 5.3.4. Analysis of Discontinued Clinical Trials by Geography
- 5.3.5. Analysis of Discontinued Clinical Trials by Reason of Discontinuation
5.4. Concluding Remarks

6. PARTNERSHIPS AND COLLABORATIONS

6.1. Chapter Overview
6.2. Partnership Models
6.3. Depressive Disorders: List of Partnerships and Collaborations
- 6.3.1. Analysis by Year of Partnerships
- 6.3.2. Analysis by Type of Partnership
- 6.3.3. Analysis by Type and Year pf Partnership
- 6.3.4. Analysis by Area of Focus
- 6.3.5. Analysis by Type of Depressive Disorder
- 6.3.6. Regional Analysis
  - 6.3.6.1. Local and International Agreements
  - 6.3.6.2. Intercontinental and Intracontinental Agreements
- 6.3.7. Most Active Players: Analysis by Number of Partnerships
- 6.3.8. Big Pharma Players

7. FUNDING AND INVESTMENT ANALYSIS

7.1. Chapter Overview
7.2. Types of Funding
7.3. Depressive Disorders: Funding and Investment Analysis
- 7.3.1. Analysis by Number of Instances
- 7.3.2. Analysis by Amount Invested
- 7.3.3. High Value Deals: Analysis by Year
- 7.3.4. Analysis by Type of Funding
- 7.3.5. Analysis by Number of Funding Instances across Different Therapeutic Areas
- 7.3.6. Most Active Players
- 7.3.7. Most Active Investors
7.4. Concluding Remarks

8. CLINICAL TRIAL ANALYSIS

8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Depressive Disorders: Clinical Trial Analysis
- 8.3.1. Analysis by Trial Registration Year
- 8.3.2. Analysis by Trial Phase
- 8.3.3. Analysis by Recruitment Status
- 8.3.4. Analysis by Type of Sponsor / Collaborator
- 8.3.5. Analysis by Type of Depressive Disorder
- 8.3.6. Analysis by Type of Drug Class
- 8.3.7. Most Active Players
- 8.3.8. Analysis by Number of Clinical Trials and Geography
- 8.3.9. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
- 8.3.10. Analysis by Number of Clinical Trials, Type of Depressive Disorder and Geography
- 8.3.11. Analysis by Number of Clinical Trials, Type of Depressive Disorder, Trial Phase and Geography
- 8.3.12. Analysis by Number of Clinical Trials, Type of Drug Class and Geography
- 8.3.13. Analysis by Number of Clinical Trials, Type of Drug Class, Trial Phase and Geography
- 8.3.14. Analysis by Enrolled Patient Population and Geography
- 8.3.15. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
- 8.3.16. Analysis by Enrolled Patient Population, Type of Depressive Disorder and Geography
- 8.3.17. Analysis by Enrolled Patient Population, Type of Depressive Disorder, Trial Phase and Geography
- 8.3.18. Analysis by Enrolled Patient Population, Type of Drug Class and Geography
- 8.3.19. Analysis by Enrolled Patient Population, Type of Drug Class, Trial Phase and Geography
8.4. Concluding Remarks
- 8.4.1. Emerging Molecules to Watch
- 8.4.2. Most Important Trials to Watch

9. CLINICAL TRIAL ENDPOINTS ANALYSIS

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Overview of the Most Common Primary Endpoints
9.4. Primary Endpoints Evaluated for Major Depressive Disorder: Comparative Analysis of Late-Stage Drugs
9.5. Primary Endpoints Evaluated for Bipolar Disorder: Comparative Analysis of Late-Stage Drugs
9.6. Primary Endpoints Evaluated for Other Types of Depressive Disorder: Comparative Analysis of Late-Stage Drugs

10. CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS

10.1. Chapter Overview
10.2. Methodology
- 10.2.1. Assumptions and Key Parameters
10.3. Clinical and Commercial Attractiveness Analysis: Depressive Disorders
- 10.3.1. Clinical and Commercial Attractiveness Analysis: Major Depressive Disorder
- 10.3.2. Clinical and Commercial Attractiveness Analysis: Bipolar Disorder
- 10.3.3. Clinical and Commercial Attractiveness Analysis: Other Types of Depressive Disorder

11. KEY COMMERCIALIZATION STRATEGIES

11.1. Chapter Overview
11.2. Successful Drug Launch Strategy: ROOTS Framework
11.3. Successful Drug Launch Strategy: Product Differentiation
11.4. Commercialization Strategies Adopted Based on Development Stage of Product
11.5. Approved Molecules for Treating Depressive Disorders
- 11.5.1. Abilify Mycite(R)
- 11.5.2. Abilify Maintena(R)
- 11.5.3. Rexulti(R)
- 11.5.4. Vraylar (R)
- 11.5.5. Trintellix(R)
- 11.5.6. Fetzima(R)
- 11.5.7. Latuda(R)
- 11.5.8. Viibryd(R)
11.6. Key Commercialization Strategies Adopted by Companies Focused on Depressive Disorders
- 11.6.1. Strategies Adopted Before the Approval of Drug
  - 11.6.1.1. Participation in Global Events
- 11.6.2. Strategies Adopted During the Launch of Drug
  - 11.6.2.1. Collaboration with Internal Stakeholders and Pharmaceutical Firms
  - 11.6.2.2. Awareness through Product Websites
  - 11.6.2.3. Direct to Consumer (DTC) Advertisements
- 11.6.3. Strategies Adopted Post Drug Launch / Near Patent Expiry of Drug
  - 11.6.3.1. Approval of Drug in Multiple Geographies
  - 11.6.3.2. Approval of Drug for Multiple Indications
11.7. Concluding Remarks

12. DIGITAL THERAPEUTICS FOR DEPRESSIVE DISORDERS

12.1. Chapter Overview
12.2. An Overview of Digital Therapeutics
12.3. Development and Commercialization Pathway for Digital Therapeutics
- 12.3.1. Discovery and Preclinical Research
- 12.3.2. Clinical Trials and Validation
- 12.3.3. Engaging Insurance Providers / Payers
- 12.3.4. Distribution and Marketing
12.4. Digital Therapeutics for Depressive Disorders
- 12.4.1. Standalone Software Applications
- 12.4.2. Personal Coaching
- 12.4.3. AI Support
- 12.4.4. Gaming Solutions
12.5. Concluding Remarks

13. CONCLUDING REMARKS

13.1. Chapter Overview
13.2. Key Takeaways

うつ病性障害市場：業界動向と世界の予測 - うつ病タイプ別、分子タイプ別、治療タイプ別、投与経路別、主要地域別

Depressive Disorders Market: Industry Trends and Global Forecasts - Distribution by Type of Depression, Type of Molecule, Type of Therapy, Route of Administration and Key Geographical Regions

うつ病性障害市場：概要

うつ病性障害市場：成長と動向

うつ病性障害市場：主要インサイト

うつ病性障害市場における参入企業例

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 パイプラインレビュー：市販済みおよび臨床段階の医薬品

第5章 ケーススタディ：中止された医薬品開発プログラム

第6章 パートナーシップとコラボレーション

第7章 資金調達と投資分析

第8章 臨床試験の分析

第9章 臨床試験エンドポイント分析

第10章 臨床的および商業的魅力分析

第11章 主要な商業化戦略

第12章 うつ病に対するデジタル治療法

第13章 結論

第14章 付録1：表形式データ

第15章 付録2：企業・団体一覧

List of Tables

List of Figures

DEPRESSIVE DISORDERS MARKET: OVERVIEW

DEPRESSIVE DISORDERS MARKET: GROWTH AND TRENDS

DEPRESSIVE DISORDERS MARKET: KEY INSIGHTS

Example Players in the Depressive Disorders Market

DEPRESSIVE DISORDERS MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. PIPELINE REVIEW: MARKETED AND CLINICAL STAGE DRUGS

5. CASE STUDY: DISCONTINUED DRUG DEVELOPMENT PROGRAMS

6. PARTNERSHIPS AND COLLABORATIONS

7. FUNDING AND INVESTMENT ANALYSIS

8. CLINICAL TRIAL ANALYSIS

9. CLINICAL TRIAL ENDPOINTS ANALYSIS

10. CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS

11. KEY COMMERCIALIZATION STRATEGIES

12. DIGITAL THERAPEUTICS FOR DEPRESSIVE DISORDERS

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

第1章序文

第2章エグゼクティブサマリー

第3章イントロダクション

第4章パイプラインレビュー：市販済みおよび臨床段階の医薬品

第5章ケーススタディ：中止された医薬品開発プログラム

第6章パートナーシップとコラボレーション

第7章資金調達と投資分析

第8章臨床試験の分析

第9章臨床試験エンドポイント分析

第10章臨床的および商業的魅力分析

第11章主要な商業化戦略

第12章うつ病に対するデジタル治療法

第13章結論

第14章付録1：表形式データ

第15章付録2：企業・団体一覧